Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Hematologic Diseases × fludarabine × Clear all

Phase

Status

Sponsor Class

OTHER 12 NETWORK 2 OTHER_GOV 1 NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 3 Leukemia 3 Burkitt Lymphoma 3 Solid Tumors 1 Solid Tumor 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Lymphoma 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited 1

Interventions

fludarabine phosphate 1 fludarabine 1 Injections 1 Cyclophosphamide 1 COVID-19 Vaccines 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05755854 2023-09-22

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

Anhui Provincial Hospital

Phase 1 Unknown

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡